nivolumab,ipilimumab,cabozantinib
bms
['ipi+', ' ipi ', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'cabo ', 'nivo']
very interesting presentation from on comic-313, showing continued pfs benefit with triplet nivo+ipi+cabo, but surprisingly not clear benefit in imdc poor risk, despite similar drug exposure and similar toxicity. #gu23 
Oncologist, physician-scientist, Assistant Professor @YaleCancer @YaleMed | cancer immunotherapy, genomics, kidney cancer | tweets ≠ medical advice.